{"ModuleTitle": "Company Description", "CompanyName": "Atossa Therapeutics, Inc.", "Symbol": "ATOS", "Address": "107 SPRING STREET, SEATTLE, Washington, 98104, United States of America", "Phone": "206.588.0256", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a clinical-stage biopharmaceutical company focused on developing novel\r\nproprietary therapeutics and delivery methods for the treatment of breast cancer\r\nand other breast conditions. Our lead program is the development of Endoxifen,\r\nan active metabolite of tamoxifen which is an FDA-approved drug, to treat and\r\nprevent breast cancer in high risk women. Our primary goal is to develop our\r\nproprietary oral Endoxifen to reduce mammographic breast density (or, MBD),\r\nwhich is an emerging public health issue affecting over 10 million women in the\r\nUnited States. Studies conducted by others have shown that MBD increases the\r\nrisk of developing breast cancer and that reducing MBD can reduce the incidence\r\nof breast cancer. In December 2019, we contracted with Stockholm South General\r\nHospital to conduct a double-blinded, placebo-controlled Phase 2 study of our\r\noral Endoxifen in approximately 1,000 pre-menopausal women with MBD who will be\r\ndosed over six months.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f26%2f0001437749-20-006155.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Kyle Guse", "title": "CFO, Secretary & Chief Accounting Officer"}, {"name": "Steven C. Quay", "title": "Chairman, President & Chief Executive Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}